Stockreport

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Asso...

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF RP-A501 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and =10% reduction in LV mass index at 12 months and sustained [Read more]